Suchergebnisse - "Melzer Cohen, Cheli"

PubPharm (55)

1

Pharmaceutical Agents as Potential Drivers in the Development of Early-Onset Colorectal Cancer : Case-Control Study

enthalten in: JMIR public health and surveillance | 2023

von Ben-Aharon, I. | Rotem, R. | Melzer-Cohen, C. | +6

2

Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease : Real-world data

enthalten in: Diabetes, obesity & metabolism | 2023

von Schechter, M. | Melzer Cohen, C. | Zelter, T. | +5

3

Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes : An Individual-Participant Data Meta-Analysis

enthalten in: JAMA | 2023

von Writing Group for the CKD Prognosis Consortium | Grams, M. | Coresh, J. | +178

4

Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease

enthalten in: Clinical journal of the American Society of Nephrology : CJASN | 2023

von Melzer Cohen, C. | Schechter, M. | Rozenberg, A. | +7

CommentIn: Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1119-1121. - PMID 37498620

5

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease : EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

enthalten in: Cardiovascular diabetology | 2023

von Vistisen, D. | Carstensen, B. | Elisabetta, P. | +54

6

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

enthalten in: Cardiovascular diabetology | 2023

von Vistisen, D. | Carstensen, B. | Elisabetta, P. | +26

7

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

enthalten in: Cardiovascular diabetology | 2023

von Vistisen, D. | Carstensen, B. | Elisabetta, P. | +26

8

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes : real-world evidence

enthalten in: Cardiovascular diabetology | 2023

von Schechter, M. | Melzer Cohen, C. | Fishkin, A. | +9

9

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence

enthalten in: Cardiovascular diabetology | 2023

von Schechter, M. | Melzer Cohen, C. | Fishkin, A. | +9

10

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia : Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

enthalten in: Diabetes & metabolism | 2023

von Karasik, A. | Lanzinger, S. | Chia-Hui Tan, E. | +26

1
2
3
4
5
6
Nächster »
[6]